Medication & Treatment Flashcards
1
Q
Monitoring needed in long-term PPI use (3)
A
magnesium
calcium
B12
2
Q
Long-term risks of PPIs (2)
A
osteoporosis
renal dysfunction
3
Q
Metoclopramide dose (gastroparesis)
A
10-15 mg 3-4 times daily
4
Q
Botox dose (achalasia, esophageal spasms)
A
100-200 units at LES
5
Q
Dantrolene dose (diffuse esophageal spasm)
A
25 mg qday, increase as needed
6
Q
Lansoprazole brand name
A
prevacid
7
Q
Lansoprazole (prevacid) dose
A
15-30 mg daily
8
Q
Potential drug interaction with pantoprazole (protonix)
A
clopidogrel
9
Q
Mesalamine brand names (2)
A
asacol
lialda
10
Q
Mesalamine dose (UC, Crohn’s)
A
2.4-4.8 g daily
11
Q
Infliximab brand name
A
remicade
12
Q
Infliximab dose (UC, Crohn’s)
A
5-10 mg/kg q8 weeks
13
Q
Adalimumab brand name
A
humira
14
Q
Adalimumab dose (UC, Crohn’s)
A
160 mg then 80 mg
15
Q
Vedolizumab brand name
A
entyvio
16
Q
Vedolizumab dose (UC, Crohn’s)
A
300 mg q4-8 weeks
17
Q
Ustekinumab brand name
A
stelara
18
Q
Ustekinumab dose (UC, Crohn’s)
A
130 mg initial then 90 mg q8-12 weeks
19
Q
Linaclotide brand name
A
linzess
20
Q
Linaclotide dose (IBS-C)
A
145 mcg daily
21
Q
Lubiprostone brand name
A
amitiza
22
Q
Lubiprostone dose (IBS-C, chronic idiopathic constipation)
A
8-24 mcg BID
23
Q
Rifaximin brand name
A
xifaxan
24
Q
Rifaximin dose (IBS-D, hepatic encephalopathy)
A
550 mg BID for 14 days
25
Budesonide brand name (2)
entocort
uceris
26
Budesonide dose (UC, Crohn's)
9 mg daily
27
Lab monitoring needed for long-term budesonide treatment
bone density
28
Prednisone brand name
deltasone
29
Prednisone dose (severe IBD, autoimmune hepatitis)
40-60 mg daily
30
Ursodiol brand name
actigall
31
Ursodiol dose (PBC)
300 mg BID
32
Promethazine brand name
phenergan
33
Promethazine dose (N/V)
25 mg q4-6 hours prn
34
Loperamide dosing
2-4 mg prn
35
Maximum daily loperamide dose
16 mg
36
Hyoscyamine brand name
levsin
37
Hyoscyamine dose (IBS, abdominal cramps)
0.125-0.25 mg q4h prn
38
Dicyclomine brand name
bentyl
39
Dicyclomine dose (IBS - cramping)
10-20 mg QID
40
Metronidazole dose (C. diff, intra-abdominal infections)
500 mg TID for 10-14 days
41
Ciprofloxacin dose (infectious diarrhea)
500 mg BID for 7-14 days
42
Plecanatide brand name
trulance
43
Plecanatide dose (IBS-C, chronic idiopathic constipation)
3 mg daily
44
Alosetron brand name
lotronex
45
Alosetron dose (severe IBS-D in women)
0.5-1 mg BID
46
Risk associated with alosetron
ischemic colitis
47
Tacrolimus brand name
prograf
48
Tacrolimus dose (refractory IBD)
0.05-0.2 mg/kg daily
49
Azathioprine brand name
imuran
50
Azathioprine dose (IBD, autoimmune hepatitis)
1-2.5 mg/kg daily
51
6-mercaptopurine brand name
purinethol
52
6-mercaptopurine dose (IBD - maintenance only)
1-1.5 mg/kg daily
53
Eluxadoline brand name
viberzi
54
Eluxadoline dose (IBS-D)
75-100 mg BID
55
Bezlotoxumab (zinplava) dose (prevention of C. diff recurrence)
10 mg/kg IV once
56
Erythromycin dose (gastroparesis)
250-500 mg TID
57
Octreotide dose (variceal bleed, neuroendocrine tumor)
50-100 mcg SC BID
58
Methotrexate dose (Crohn's)
15-25 mg weekly
59
Balsalazide brand name
colazal
60
Balsalazide dose (UC)
2.25 g TID
61
Major benefit of balsalazide
targeted colonic release
62
Natalizumab (tysabri) dose (refractory Crohn's)
300 mg q4 weeks
63
Infliximab (remicade) MOA
TNF-alpha inhibitor
64
Adalimumab (humira) MOA
TNF-alpha inhibitor
65
Vedolizumab (entyvio) MOA
integrin inhibitor
66
Ustekinumab (stelara) MOA
IL-12 and IL-23 inhibitor
67
Tofacitinib brand name
xeljanz
68
Tofacitinib (xeljanz) MOA
janus kinase inhibitor
69
Tofacitinib dose (moderate to severe UC)
xeljanz: 10 mg BID for 8 weeks, then 5 mg
xeljanz XR: 11 mg once daily
70
Monitoring required for tofacitinib (xeljanz)
monitoring for thrombosis
71
PO regimen for diverticulitis
500 mg cipro BID + 500 mg metronidazole TID x 7-10 days
72
Non-severe C. diff treatment
vancomycin 125mg QID x 10 days
73
Severe C. diff treatment
vancomycin 500 mg QID + IV metronidazole
74
Microscopic colitis treatment
budesonide 9 mg/day for 6-8 weeks
75
Amoxicillin dose (H. pylori eradication)
1000 mg BID
76
Sucralfate dose
1 g QID
77
Metoclopramide dose
10 mg TID
78
Giardia treatment
metronidazole 250-500 mg TID for 5-7 days
79
Amebiasis treatment
1) metronidazole 750 mg TID for 7-10 days then
2) iodoquinol 650 mg TID for 20 days
80
PPI and its dose for Zollinger-Ellison Syndrome
omeprazole 60 mg BID
81
H. pylori quadruple therapy
1) PPI BID (omeprazole 20mg, lansoprazole 30mg, pantoprazole 40mg, esomeprazole 40mg)
2) bismuth subsalicylate 524mg QID
3) antibiotic #1 (tetracycline 500mg QID)
4) antibiotic #2 (metronidazole 500mg TID or clarithromycin 500mg BID)
82
Docusate MOA
surfactant
83
Miralax MOA
osmotic laxative
84
PPI drip rate in upper GI bleed
8 mg/hr
85
Gut-specific biologic
vedolizumab (entyvio)
86
Common screening not needed for vedolizumab (entyvio)
TB
87
Upadacitinib brand name
rinvoq
88
Upadacitinib (rinvoq) MOA
JAK-1 selective inhibitor
89
UC specific biologics (2)
tofacitinib (xeljanz)
upadacitinib (rinvoq)
90
Risankizumab brand name
skyrizi
91
Risankizumab (skyrizi) MOA
IL-23 (p19 subunit) inhibitor
92
Biologic that is Crohn's specific
risankizumab (skyrizi)
93
Most sedating TCA
amitriptyline
94
TCA for IBS w/ best side-effect profile
desipramine
95
Best TCA for IBS-C
desipramine
96
PPI w/ best absorption
esomeprazole
97
Upadacitinib (rinvoq) MOA
selective JAK1 inhibitor
98
Risankizumab (skyrizi) MOA
selective IL-23 inhibitor
99
Tofacitinib (xeljanz) MOA
JAK1/3 inhibitor
100
Medication particularly helpful for postprandial abdominal pain
dicyclomine
101
Three most common medication classes for causing microscopic colitis
NSAIDs
PPIs
SSRIs
102
IBS-D medication only indicated in women
alosetron (lotronex)
103
Post-ERCP indomethacin dose
100 mg
104
Mesalamine dose
2.4-4.8 g/day
105
Azathioprine dose
2-2.5 mg/kg/day
106
Medications used to treat IBS-D (2)
alosetron (lotronex) 0.5-1mg BID
eluxadoline (viberzi) 75-100mg BID
107
Eluxadoline (viberzi) dose and indication
75-100mg BID, IBS-D
108
Alosetron (lotronex) dose and indication
0.5-1mg BID, IBS-D (women and severe cases only)
109
Eluxadoline (viberzi) contraindication
biliary obstruction
110
Alosetron (lotronex) risk
ischemic colitis
111
Medication for IBS-D reserved for women and severe cases
alosetron (lotronex)
112
Medications used to treat IBS-C (3)
linaclotide (linzess) 145mcg
lubiprostone (amitiza) 8-24mg BID
Plecanatide (trulance) 3mg qday
113
Linaclotide (linzess) dose and indication
145mcg, IBS-C
114
Lubiprostone (amitiza) dose and indication
8-24mg, IBS-C
115
Plecanatide (trulance) dose and indication
3mg, IBS-C
116
Plecanatide (trulance) contraindication
age < 6
117
Giardia treatment
flagyl 250-500mg TID for 5-7 days
118
Entamoeba histolytic treatment (2)
flagyl 750mg TID for 7-10 days followed by iodoquinol 650mg TID for 20 days
119
Salmonella treatment (severe and non-severe)
severe: cipro 500mg BID for 5-7 days
non-severe: supportive care
120
Quadruple therapy medications (4)
bismuth
flagyl
tetracycline
PPI
121
Bismuth quadruple therapy dose
300mg QID
122
Flagyl quadruple therapy dose
500mg TID
123
Tetracycline quadruple therapy dose
500mg QID
124
PPI quadruple therapy dose
BID (ie: omeprazole 20-40mg, protonix 40mg)
125
Quadruple therapy
bismuth 300mg QID
flagyl 500mg TID
tetracycline 500mg QID
PPI BID
126
Alternative names for mesalamine (2)
lialda
asacol
127
Alternative name for infliximab and dose
remicade
5-10 mg/kg q8wks
128
Alternative name for adalimumab and dose
humira
160mg then 80mg
129
Alternative name for vedolizumab and dose
entyvio
300mg q4-8wks
130
Unique, beneficial aspect of entyvio
gut-selective
131
Alternative name for ustekinumab and dose
stelara
90mg q8-12wk
132
Alternative names for budesonide (2)
entocort
uceris
133
Alternative name for ursodial
actigall
134
Bezlotoxumab (zinplava) use
prevents C diff recurrence
135
Bezlotoxumab (zinplava) dose
10 mg/kg IV x1
136
Alternative name for balsalazide
colazal
137
Balsalazide (colazal) dose
2.25g TID
138
Balsalazide (colazal) advantageous characteristic
targeted colonic release
139
Natalizumab alternative name
tysabri
140
Natalizumab (tysabri) indication
refractory Crohn's
141
Natalizumab (tysabri) dose
300mg q4wks
142
Work-up prior to initiating natalizumab (tysabri) (2)
JC virus antibody
MRI
143
Natalizumab (tysabri) risk
PML
144
Infliximab (remicade) MOA
TNF-alpha inhibitor
145
Adalimumab (humira) MOA
TNF-alpha inhibitor
146
Vedolizumab (entyvio) MOA
integrin inhibitor
147
Ustekinumab (stelara) MOA
IL-12, -23
148
Ustekinumab (stelara) dose
130mg then 90mg SQ
149
Tofacitinib (xeljanz) MOA
JAK-inhibitor
150
Tofacitinib (xeljanz) dose
10mg BID PO for 8 wks then 5mg
151
Tofacitinib (xeljanz) monitoring
thrombosis
152
Risankizumab (skyrizi) MOA
IL-23 p19 subunit
153
Risankizumab (skyrizi) dose
600mg IV @ wk 0, 4, 8 then
300mg SQ q8 wks
154
Risankizumab (skyrizi) indications
Crohn's only
155
Upadacitinib (rinvoq) MOA
JAK-1
156
Upadacitinib (rinvoq) dose
45mg PO for 8 wks then 15mg or 30mg qday
157
Upadacitinib (rinvoq) indications
UC and Crohn's
158
Guselkumab (tremfya) MOA
IL-23 p19 subunit
159
Guselkumab (tremfya) dose
100mg SQ q4 wks
